Post-IPO Zentalis Plows New Ground With China Oncology Venture

US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio. 

Shanghai
Zentalis Sets Up Shanghai-Based JV • Source: Shutterstock

US venture Zentalis Pharmaceuticals, Inc. broke new ground when it raised around $190m in its successful Nasdaq IPO in early April after becoming the first company to hold an all-virtual roadshow and bell ringing ceremony on its trading debut.

It is now looking to break more ground outside the US with the establishment of a new joint venture in China that will take forward both in this market and globally three

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia